TORONTO, ON--(Marketwired - September 02, 2013) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, today announced an Agreement in Principle to acquire a leading Canadian OTC healthcare company. Upon completion of the acquisition, the company will bring current sales and a valuable IP portfolio to Axxess Pharma.
The Canadian Corporation, based in Toronto, has an attractive IP portfolio including a best-selling, patented, OTC pain relief formula. The company also has a number of unique formulas and world class brand products that Axxess Pharma will be able to immediately leverage, with existing distribution.
The company will also bring a number of experienced executives to Axxess Pharma to assist in growing sales across North America, and online.
Dr. Bagi, President of Axxess Pharma Inc. stated, "We anticipate completing the final agreement within 30 days. This acquisition will facilitate access to capital and generate a rapid ramp-up of sales. We anticipate major revenue growth in the near term with this aquisition."
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.
Safe Harbor Statement:
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.